Does the media refer more to ROIV or IMVT?

In the previous week, Roivant Sciences had 3 more articles in the media than Immunovant. MarketBeat recorded 13 mentions for Roivant Sciences and 10 mentions for Immunovant. Immunovant's average media sentiment score of 0.38 beat Roivant Sciences' score of 0.37 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 3 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMVT or INSM more profitable?

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Immunovant's return on equity of -69.59% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% Insmed -76.94% -123.94% -44.30%

Does the media favor IMVT or INSM?

In the previous week, Immunovant and Immunovant both had 10 articles in the media. Insmed's average media sentiment score of 0.66 beat Immunovant's score of 0.38 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral Insmed 3 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, INCY or IMVT?

Incyte has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.14B 4.91 $1.29B $7.85 15.88 Immunovant N/A N/A -$505.61M -$2.82 N/A

Is INCY or IMVT more profitable?

Incyte has a net margin of 27.71% compared to Immunovant's net margin of 0.00%. Incyte's return on equity of 29.93% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% Immunovant N/A -69.59% -62.49%

Does the media prefer INCY or IMVT?

In the previous week, Incyte had 11 more articles in the media than Immunovant. MarketBeat recorded 21 mentions for Incyte and 10 mentions for Immunovant. Incyte's average media sentiment score of 0.45 beat Immunovant's score of 0.38 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 5 Very Positive mention(s) 8 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IMVT or BNTX more profitable?

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -69.59% -62.49% BioNTech -63.54% -6.86% -6.00%

Does the media prefer IMVT or BNTX?

In the previous week, BioNTech had 10 more articles in the media than Immunovant. MarketBeat recorded 20 mentions for BioNTech and 10 mentions for Immunovant. Immunovant's average media sentiment score of 0.38 beat BioNTech's score of 0.16 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral BioNTech 8 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer IMVT or UTHR?

In the previous week, United Therapeutics had 10 more articles in the media than Immunovant. MarketBeat recorded 20 mentions for United Therapeutics and 10 mentions for Immunovant. United Therapeutics' average media sentiment score of 0.73 beat Immunovant's score of 0.38 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 4 Negative mention(s) 0 Very Negative mention(s) Neutral United Therapeutics 12 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunovant (IMVT) Competitors

$34.54 -2.75 (-7.37%)

Closing price 04:00 PM Eastern

Extended Trading

$34.35 -0.19 (-0.55%)

As of 07:35 PM Eastern

Compare

IMVT vs. ROIV, INSM, INCY, BNTX, and UTHR

Should you buy Immunovant stock or one of its competitors? Immunovant's main competitors and comparable companies include Roivant Sciences (ROIV), Insmed (INSM), Incyte (INCY), BioNTech (BNTX), and United Therapeutics (UTHR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Immunovant compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Immunovant has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
Immunovant	N/A	-69.59%	-62.49%

64.8% of Roivant Sciences shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 8.8% of Roivant Sciences shares are held by insiders. Comparatively, 1.9% of Immunovant shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Roivant Sciences currently has a consensus price target of $45.64, suggesting a potential upside of 23.94%. Immunovant has a consensus price target of $44.00, suggesting a potential upside of 27.39%. Given Immunovant's higher possible upside, analysts plainly believe Immunovant is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Roivant Sciences has higher revenue and earnings than Immunovant. Roivant Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,219.83	-$299.77M	-$0.53	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

In the previous week, Roivant Sciences had 3 more articles in the media than Immunovant. MarketBeat recorded 13 mentions for Roivant Sciences and 10 mentions for Immunovant. Immunovant's average media sentiment score of 0.38 beat Roivant Sciences' score of 0.37 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	3 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Roivant Sciences beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Immunovant compare to Insmed?

Immunovant (NASDAQ:IMVT) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

47.1% of Immunovant shares are held by institutional investors. 1.9% of Immunovant shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Immunovant has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Immunovant's return on equity of -69.59% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
Insmed	-76.94%	-123.94%	-44.30%

Immunovant currently has a consensus price target of $44.00, suggesting a potential upside of 27.39%. Insmed has a consensus price target of $204.91, suggesting a potential upside of 73.16%. Given Insmed's stronger consensus rating and higher possible upside, analysts clearly believe Insmed is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Immunovant has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, Insmed has a beta of 0.82, meaning that its share price is 18% less volatile than the broader market.

In the previous week, Immunovant and Immunovant both had 10 articles in the media. Insmed's average media sentiment score of 0.66 beat Immunovant's score of 0.38 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
Insmed	3 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
Insmed	$606.42M	42.62	-$1.28B	-$4.11	N/A

Summary

Insmed beats Immunovant on 9 of the 14 factors compared between the two stocks.

How does Immunovant compare to Incyte?

Incyte (NASDAQ:INCY) and Immunovant (NASDAQ:IMVT) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, media sentiment, profitability, risk, institutional ownership and analyst recommendations.

Incyte presently has a consensus price target of $124.05, suggesting a potential downside of 0.47%. Immunovant has a consensus price target of $44.00, suggesting a potential upside of 27.39%. Given Immunovant's stronger consensus rating and higher possible upside, analysts plainly believe Immunovant is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Incyte has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.14B	4.91	$1.29B	$7.85	15.88
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A

97.0% of Incyte shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 1.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Incyte has a net margin of 27.71% compared to Immunovant's net margin of 0.00%. Incyte's return on equity of 29.93% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Immunovant	N/A	-69.59%	-62.49%

Incyte has a beta of 0.77, indicating that its share price is 23% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.81, indicating that its share price is 19% less volatile than the broader market.

In the previous week, Incyte had 11 more articles in the media than Immunovant. MarketBeat recorded 21 mentions for Incyte and 10 mentions for Immunovant. Incyte's average media sentiment score of 0.45 beat Immunovant's score of 0.38 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	5 Very Positive mention(s)	8 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Incyte beats Immunovant on 12 of the 15 factors compared between the two stocks.

How does Immunovant compare to BioNTech?

Immunovant (NASDAQ:IMVT) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation, analyst recommendations and media sentiment.

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
BioNTech	-63.54%	-6.86%	-6.00%

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 1.9% of Immunovant shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, BioNTech had 10 more articles in the media than Immunovant. MarketBeat recorded 20 mentions for BioNTech and 10 mentions for Immunovant. Immunovant's average media sentiment score of 0.38 beat BioNTech's score of 0.16 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
BioNTech	8 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Immunovant presently has a consensus target price of $44.00, suggesting a potential upside of 27.39%. BioNTech has a consensus target price of $126.00, suggesting a potential upside of 27.97%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

Immunovant has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
BioNTech	$3.25B	7.67	-$1.29B	-$7.83	N/A

Immunovant has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

Summary

BioNTech beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Immunovant compare to United Therapeutics?

Immunovant (NASDAQ:IMVT) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

In the previous week, United Therapeutics had 10 more articles in the media than Immunovant. MarketBeat recorded 20 mentions for United Therapeutics and 10 mentions for Immunovant. United Therapeutics' average media sentiment score of 0.73 beat Immunovant's score of 0.38 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	4 Negative mention(s)	0 Very Negative mention(s)	Neutral
United Therapeutics	12 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant currently has a consensus price target of $44.00, indicating a potential upside of 27.39%. United Therapeutics has a consensus price target of $646.00, indicating a potential upside of 31.99%. Given United Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe United Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

47.1% of Immunovant shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 1.9% of Immunovant shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.82	N/A
United Therapeutics	$3.18B	6.60	$1.33B	$27.95	17.51

United Therapeutics has a net margin of 41.56% compared to Immunovant's net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-69.59%	-62.49%
United Therapeutics	41.56%	20.18%	17.98%

Immunovant has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Summary

United Therapeutics beats Immunovant on 13 of the 14 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMVT vs. The Competition

Export

Metric	Immunovant	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.70B	$3.90B	$7.21B	$13.10B
Dividend Yield	N/A	3.64%	2.53%	13.00%
P/E Ratio	N/A	13.95	274.58	25.69
Price / Sales	N/A	1,357.85	639.38	80.65
Price / Cash	N/A	109.50	76.31	52.02
Price / Book	8.24	15.30	10.44	6.32
Net Income	-$505.61M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-5.06%	-0.22%	0.51%	1.35%
1 Month Performance	-22.15%	-6.06%	-3.38%	-3.68%
1 Year Performance	131.81%	34.37%	16.04%	5.56%

Immunovant Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMVT Immunovant	2.8724 of 5 stars	$34.54 -7.4%	$44.00 +27.4%	+139.2%	$7.70B	N/A	N/A	315	Trending News Analyst Forecast Gap Down High Trading Volume
ROIV Roivant Sciences	3.2112 of 5 stars	$41.02 +0.5%	$40.63 -1.0%	+155.8%	$29.49B	$8.26M	N/A	721
INSM Insmed	3.1973 of 5 stars	$125.30 -3.2%	$205.52 +64.0%	-16.7%	$28.26B	$606.42M	N/A	1,664
INCY Incyte	3.1346 of 5 stars	$122.19 +0.6%	$124.05 +1.5%	+49.8%	$24.62B	$5.82B	15.57	2,844	Trending News Analyst Forecast
BNTX BioNTech	3.96 of 5 stars	$98.86 +2.2%	$126.00 +27.5%	+2.2%	$24.46B	$2.65B	N/A	7,807	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMVT) was last updated on 9/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunovant (IMVT) Competitors

IMVT vs. ROIV, INSM, INCY, BNTX, and UTHR

How does Immunovant compare to Roivant Sciences?

Summary

How does Immunovant compare to Insmed?

Summary

How does Immunovant compare to Incyte?

Summary

How does Immunovant compare to BioNTech?

Summary

How does Immunovant compare to United Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunovant (IMVT) Competitors

IMVT vs. ROIV, INSM, INCY, BNTX, and UTHR

How does Immunovant compare to Roivant Sciences?

Which has more volatility & risk, ROIV or IMVT?

Is ROIV or IMVT more profitable?

Do institutionals & insiders hold more shares of ROIV or IMVT?

Do analysts recommend ROIV or IMVT?

Which has preferable earnings & valuation, ROIV or IMVT?

Does the media refer more to ROIV or IMVT?

Summary

How does Immunovant compare to Insmed?

Do insiders and institutionals believe in IMVT or INSM?

Is IMVT or INSM more profitable?

Do analysts prefer IMVT or INSM?

Which has more risk & volatility, IMVT or INSM?

Does the media favor IMVT or INSM?

Which has preferable valuation and earnings, IMVT or INSM?

Summary

How does Immunovant compare to Incyte?

Do analysts prefer INCY or IMVT?

Which has preferable valuation and earnings, INCY or IMVT?

Do insiders & institutionals hold more shares of INCY or IMVT?

Is INCY or IMVT more profitable?

Which has more volatility & risk, INCY or IMVT?

Does the media prefer INCY or IMVT?

Summary

How does Immunovant compare to BioNTech?

Is IMVT or BNTX more profitable?

Do institutionals and insiders hold more shares of IMVT or BNTX?

Does the media prefer IMVT or BNTX?

Do analysts prefer IMVT or BNTX?

Which has higher valuation and earnings, IMVT or BNTX?

Which has more volatility & risk, IMVT or BNTX?

Summary

How does Immunovant compare to United Therapeutics?

Does the media prefer IMVT or UTHR?

Do analysts recommend IMVT or UTHR?

Do institutionals and insiders believe in IMVT or UTHR?

Which has stronger valuation & earnings, IMVT or UTHR?

Is IMVT or UTHR more profitable?

Which has more volatility and risk, IMVT or UTHR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools